张静
ZHANG Jing

• 1:陕西省安康市中医院儿科

摘要(Abstract)：

目的:观察孟鲁司特联合布地奈德治疗儿童咳嗽变异性哮喘(CVA)的临床疗效。方法:180例CVA患儿随机分为孟鲁司特组(A组)、布地奈德组(B组)、孟鲁司特联合布地奈德(C组),分别给予相应药物治疗2月,观察3组患儿的临床疗效、治疗前后肺活量(FVC)、第1秒末用力呼气量(FEV1)及呼气峰流速百分比(PEF%),哮喘发作次数、咳嗽持续时间及肺部哮鸣音存在时间,评价3组CVA患儿的治疗效果。结果:C组总有效率93.3%A组总有效率80.0%,B组总有效率78.3%,C组与A组、B组间差异均有统计学意义(P<0.05);治疗前3组FVC、FEV1、PEF%等肺通气功能差异无统计学意义(P>0.05),治疗后3组FVC、FEV1、PEF%均较治疗前均显著改善(P<0.05),C组肺通气功能与A组、B组之间差异均有统计学意义(P<0.05),A组、B组两组肺通气功能差异无统计学意义(P>0.05);治疗后C组的哮喘发作次数较A组、B组减少,咳嗽持续时间及肺部哮鸣音存在时间短于A组、B组(P<0.05)。结论:孟鲁司特联合布地奈德治疗小儿咳嗽变异性哮喘的疗效确切,安全稳定,建议临床推广。
Objective: To explore the curative effect of montelukast and budesonide on children with cough variant asthma( CVA). Methods: A total of 180 CVA children were randomly divided into montelukast group( group A),budesonide group( group B) and montelukast combined with budesonide group( group C),and were treated with corresponding drugs respectively for 2 months. The clinical effects of three groups,vital capacity( FVC) before and after the treatment,the forced expiratory volume in 1 seconds( FEV1) and peak expiratory flow percentage( PEF%),number of asthma attacks,cough disappeared time and lung wheezing sound disappeared time were observed. Results:The total effective rate of group C was 93. 3%,group A 80. 0%,group B 78. 3%,and the differences between group C and group A,group B were statistically significant( P < 0. 05); The FVC,FEV1 and PEF % of 3 groups before treatment had no statistically significant difference( P > 0. 05),and the indicators of the three groups after treatment were significantly improved( P < 0. 05). The differences in pulmonary ventilation function between group C and group A and between group C and group B were statistically significant( P < 0. 05),and difference between group A and group B had no statistical significance( P > 0. 05); After treatment,the number of asthma attacks,cough disappeared time and lung wheezing disappeared time of group C was better than those of group A and group B( P< 0. 05). Conclusions: Montelukast and budesonide treating children with CVA is effective and safety,and it is worth wide application and promotion.

关键词(KeyWords)： 孟鲁司特;布地奈德;咳嗽变异性哮喘;儿童;疗效
montelukast;budesonide;cough variant asthma;child;curative effect

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张静
ZHANG Jing

DOI: 10.19367/j.cnki.1000-2707.2015.04.017

参考文献(References)：

• [1]肖并.孟鲁司特钠、沙丁胺醇联合布地奈德治疗小儿咳嗽变异性哮喘的疗效观察[J].中国医学创新,2011(13):139-140.
• [2]王雪梅,王卫民,董方爱.孟鲁司特与布地奈德治疗儿童咳嗽变异性哮喘的临床观察[J].哈尔滨医药,2011(3):168-169.
• [3]薛满,马春利,梁宽,等.孟鲁司特钠治疗小儿咳嗽变异性哮喘的临床疗效及安全性研究[J].现代生物医学进展,2012(17):3317-3319.
• [4]唐涛.孟鲁司特钠治疗小儿咳嗽变异性哮喘40例疗效观察[J],吉林医学,2012(7):1421-1422.
• [5]李兰,蒋虹.白三烯受体拮抗剂孟鲁司特钠治疗小儿感染后咳嗽疗效观察[J].四川医学,2013(3):302-303.
• [6]陈惠英,刘桂珍,廖朝峰,等.布地奈德与孟鲁司特治疗咳嗽变异性哮喘的疗效观察[J].实用临床医药杂志,2012(22):54-56.

文章评论(Comment)：